Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Moderna said three abstracts on intismeran autogene, its investigational mRNA-based individualized neoantigen therapy, were accepted for presentation at the ESMO Congress 2026 in Madrid on October 23-27. The headline presentation is INTerpath-001, a Phase 3 study of intismeran autogene plus pembrolizumab versus pembrolizumab alone as adjuvant treatment of resected stage IIB-IV melanoma, selected for the Presidential Symposium on October 24 with presenter Georgina V. Long.
Key figures
- Drug Name
- intismeran autogene (investigational mRNA-based individualized neoantigen therapy)
- Phase Of Trial
- Phase 3 (INTerpath-001 melanoma; INTerpath-014 NSCLC) and Phase 1 (pancreatic cancer with FOLFIRINOX)
- Congress
- ESMO Congress 2026
- Congress Dates
- October 23-27, 2026, Madrid, Spain
- Headline Session
- Presidential Symposium, Saturday, October 24, 4:30 PM CEST
- Investor Webcast
- Saturday, October 24, 7:00 PM CEST / 1:00 PM EDT, investors.modernatx.com
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.